Related Experiment Videos
The E-cadherin cell-cell adhesion pathway in urologic malignancies
R A Morton1, C M Ewing, J J Watkins
1Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA.
World Journal of Urology
|January 1, 1995
Summary
E-cadherin cell adhesion is altered in urologic cancers like prostate, bladder, and kidney. This pathway may offer new diagnostic markers and cancer treatment targets.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- E-cadherin mediated cell-cell adhesion is crucial in preventing cancer progression.
- Alterations in this pathway are common in various urologic malignancies, including prostate, bladder, and renal-cell carcinoma.
- While prostate cancer studies are mature, research in bladder and renal-cell carcinoma is emerging.
Purpose of the Study:
- To investigate the role of E-cadherin in urologic malignancies.
- To explore the diagnostic and prognostic significance of E-cadherin.
- To identify the E-cadherin pathway as a potential therapeutic target for urologic cancers.
Main Methods:
- Review of existing literature on E-cadherin in prostate, bladder, and renal-cell carcinoma.
- Analysis of immunostaining data for E-cadherin.
- Evaluation of the E-cadherin pathway as a potential therapeutic target.
Main Results:
- E-cadherin dysfunction is observed in prostate cancer, with cadherin and catenin involvement.
- Down-regulation of E-cadherin is noted in bladder cancer and renal-cell carcinoma.
- E-cadherin immunostaining shows potential for diagnostic and prognostic applications in these cancers.
Conclusions:
- The E-cadherin pathway is significantly altered in urologic malignancies.
- E-cadherin serves as a potential biomarker for diagnosis and prognosis.
- Targeting the E-cadherin pathway presents a novel therapeutic strategy for bladder, prostate, and renal-cell carcinoma.